| Application no. and date | 22744149.0 (espacenet) (Federated) (European Patent Register), 20220701 | | Patent/reg. no. and date | DK/EP 4363406, 20250910 | | Publication date | 20240508 | | Priority no. and date | US 202163217970 P, 20210702 | | EP pub. no. and date |
EP 4363406 20240508 | | Effective date | | | Applicant/owner | Astrazeneca AB, 151 85 Södertälje, SE,
Mitsubishi Tanabe Pharma Corporation, 3-2-10, Dosho-machi,
Chuo-ku,
Osaka-shi,
Osaka 541-8505, JP | | Applicant ref. no. | BB369412EPDK | | Inventor | JOHANSSON, Lars Anders Mikael,
151 Södertälje, SE,
GRADÉN, Henrik,
151 Södertälje, SE,
BERGONZINI, Giulia,
151 Södertälje, SE,
SUGAMA, Hiroshi,
Osaka-shi, Osaka 541-8505, JP,
MATSUMURA, Takehiko,
Osaka-shi, Osaka 541-8505, JP | | Representative | Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017
F-92665 Asnières-sur-Seine cedex, FR | | Opponent | | | IPC Class | C07D 237/34 (2006.01) , C07D 471/04 (2006.01) | | Title | NLRP3-INFLAMMASOMHÆMMERE | | Int. application no. | EP2022068292 | | Int. publication no. | WO2023275366 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
